BlogMajority of Canadians living with advanced stage Parkinson’s Disease will now have publicly funded access to NEUPRO®. Majority of Canadians living with advanced stage Parkinson’s Disease will now have publicly funded access to NEUPRO®. Posted Date : Jun 14, 2018 BREAKING NEWS! UCB Canada just announced that the majority of Canadians living with advanced stage Parkinson’s Disease will now have publicly funded access to NEUPRO®. The drug helps to alleviate debilitating symptoms including tremors, slow movement and stiffness. “It’s encouraging for patients living with Parkinson’s and their caregivers to know that they have treatment options at every stage of this life-changing disease,” says Joyce Gordon, Chief Executive Officer, Parkinson Canada. “As a condition that manifests itself differently from person to person, and gets worse over time, symptom control is critical.” To learn more about the funding of NEUPRO® for Canadians battling APD, read UCB Canada Inc.’s news release. Share this post: Your story matters: inspire and connect Inspire hope and connect with others by sharing your Parkinson’s journey. Your voice can make a difference. Share your story Discover more like this Sep 28, 2026 FDA Approves Tavapadon: What the Parkinson’s community in Canada needs to know Sep 10, 2026 Meet the 2026 CARE Fund recipients Sep 1, 2026 Press play on your swagger: Parkinson Canada teams up with Spotify